Search clinical trials for: Darunavir/ritonavir (DRV/r)

Total 234 results

Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Healthy

Germany
Juan A. Arnaiz

Unknown

Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir

Acquired Immune Deficiency Syndrome Virus

Spain
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) (ODIN)

Human Immunodeficiency Virus - Type 1

United States, France, United Kingdom, Germany, Taiwan, Spain, Argentina, Chile, Malaysia, Panama, Romania, South Africa, Thailand, Brazil, Puerto Rico, Austria, Hungary, Australia, Guatemala
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

HIV Infections | Tuberculosis

United States, Malawi, Puerto Rico, South Africa, Thailand, Zimbabwe, Brazil, Kenya, Uganda, India, Tanzania, Botswana
University of Liverpool
Janssen Pharmaceutica; Yaounde Central Hospital; Chantal Biya International Reference...

Completed

Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS (MANET)

HIV/AIDS

Cameroon
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

HIV-1 Infections

United States
Willem Daniel Francois Venter
Medical Research Council, South Africa

Completed

Evaluation of Low-dose Darunavir in a Switch Study (DRV)

HIV Infections

South Africa
Community Research Initiative of New England

Completed

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors (DVD)

HIV Infections

United States
ASST Fatebenefratelli Sacco
Elisa Colella, M.D.; Valentina Di Cristo, M.D.; Massimo Galli, M.D.

Completed

DRV/r + RPV QD: Efficacy and Toxicity Reduction

Human Immunodeficiency Virus

Italy
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy (DRV900100QD)

HIV Infections

Spain
ViiV Healthcare

Completed

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

HIV Infections

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
Janssen-Cilag G.m.b.H

Completed

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)

Human Immunodeficiency Virus (HIV)

Germany
Janssen-Cilag S.p.A.

Completed

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

Human Immunodeficiency Virus; HIV
Ruth M. Rothstein CORE Center
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects (DRIVESHAFT)

HIV

United States
Germans Trias i Pujol Hospital

Completed

Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens

HIV Infections

Spain
Makerere University
University of Pittsburgh; University of Nebraska; University of Liverpool

Unknown

Darunavir and Rilpivirine Interactions With Levonorgestrel Implant (DRIVE-2)

Contraception | HIV-1-infection

Uganda
Hamad Medical Corporation

Completed

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar (DOLCI)

Pneumonia | COVID | Coronavirus

Qatar
PENTA Foundation
Institut National de la Santé Et de la Recherche Médicale, France; MRC CTU... and other collaborators

Completed

Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children (SMILE)

HIV Infection

United Kingdom, Spain, Argentina, France, Mexico, Portugal, South Africa, Switzerland, Thailand, Uganda, Ukraine
ANRS, Emerging Infectious Diseases
NEAT - European AIDS Treatment Network

Completed

Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects (ANRS 143)

HIV Infections

Ireland, United Kingdom, Netherlands, France, Spain, Greece, Belgium, Germany, Denmark, Sweden, Italy, Portugal, Austria, Hungary, Poland
St Stephens Aids Trust

Completed

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects

HIV Infections

United Kingdom
Imperial College London

Terminated

The First Failure Study (FAST)

HIV Infections | HIV

United Kingdom
Tibotec Pharmaceuticals, Ireland

Terminated

TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously

HIV Infections
Fundación Huésped
Ministry of Science and Technology,Argentine; National AIDS and STD programme... and other collaborators

Completed

Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects (ANDES)

HIV-1 Infection

Argentina
ANRS, Emerging Infectious Diseases
Janssen Pharmaceuticals

Completed

Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (MOBIDIP)

HIV Infection

Cameroon, Burkina Faso, Senegal
PENTA Foundation
Baylor College of Medicine; Institut National de la Santé Et de la Recherche... and other collaborators

Not yet recruiting

Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV (UNIVERSAL2)

HIV Infections
ViiV Healthcare
GlaxoSmithKline

Completed

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Infection, Human Immunodeficiency Virus
St Stephens Aids Trust

Completed

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

HIV Infections | HIV

United Kingdom
University of Cincinnati

Completed

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study

HIV Infections

United States
Hoffmann-La Roche

Completed

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

Healthy Volunteer

United States
St Stephens Aids Trust

Completed

Double Protease Inhibitor to Darunavir Switch Study

HIV Infections

United Kingdom
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

HIV | Infectious

United States, Canada, Puerto Rico
Janssen-Cilag S.p.A.

Completed

A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients (MONARCH)

Human Immunodeficiency Virus 1
Janssen-Cilag S.p.A.

Completed

Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice

HIV Infections
Janssen-Cilag International NV

Completed

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)

HIV Infections | Human Immunodeficiency Virus | Acquired Immunodeficiency Syndrome Virus | AIDS Virus

United Kingdom, Belgium, Germany, Spain, Portugal, Israel, Denmark, Russian Federation, Austria, Hungary, Switzerland
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors (MONOGEST)

Maternal-fetal Infection Transmission

France
Hospitales Universitarios Virgen del Rocío

Completed

Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy (MonDar)

HIV-infection

Spain
International Maternal Pediatric Adolescent AIDS...
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

HIV Infections

United States, Puerto Rico
Barry London

Terminated

Right Ventricular Septal Pacing in Patients With Right Bundle Branch Block and Heart Failure (The SPARK Trial) (SPARK)

Heart Failure | Right Bundle-Branch Block

United States
Tibotec BVBA

Completed

VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.

Hepatitis C | HIV | Telaprevir
University of California, Davis

Completed

Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

Human Immunodeficiency Virus Infection

United States
McGill University Health Centre/Research Institute...
Merck Sharp & Dohme LLC; CIHR Canadian HIV Trials Network

Completed

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Hepatitis C | HIV | Liver Fibrosis

Canada
St Stephens Aids Trust

Terminated

NNRTI/PI Toxicity Switch to Darunavir Study

HIV

United Kingdom
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences; Janssen-Cilag Ltd.

Completed

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

HIV-1 Infections

France
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

HIV

United States
Hannover Medical School
AbbVie

Terminated

MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV

Hepatitis C, Chronic

Germany
University of Roma La Sapienza
Istituto Superiore di Sanità

Unknown

Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy

HIV Infection

Italy
Juan A. Arnaiz

Completed

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

HIV-1

Spain
ANRS, Emerging Infectious Diseases

Recruiting

Evaluation of Third-line cART Regimen in Cambodia (3DICAM)

HIV/AIDS

Cambodia
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

HIV-1 Infection

3

Subscribe